MedTrace Logo

Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs

NCT04461925 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-07-08

No results posted yet for this study

Summary

Assessment of the clinical effects of infusions of cryopreserved allogeneic multipotent mesenchymal stem cells of the placenta and umbilical cord for COVID-19 patients with acute respiratory distress syndrome.

Conditions

Interventions

PROCEDURE

Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells

i/v infusions

DRUG

Antibiotics

per os

DRUG

Hormones

a moderate amount of dexamethasone i/v

DRUG

Anticoagulant Therapy

Sub-Q

DEVICE

Оxygen therapy

Оxygen therapy, mechanical ventilation and other supportive therapies

Sponsors & Collaborators

  • Kyiv City Clinical Hospital # 4

    collaborator UNKNOWN

  • Institute of Cell Therapy

    lead INDUSTRY

Principal Investigators

  • Peter Nemtinov, MD · Institute of Cell Therapy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-02
Primary Completion
2021-05-02
Completion
2021-12-31

Countries

  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04461925 on ClinicalTrials.gov